ROCHE - Erivedge (Vismodegib) approved for Locally Advanced or Metastatic BCC in US
Yesterday, ROG and Curis jointly announced that the USFDA approved once daily Erivedge, oral, first in class hedgehog inhibitor earlier than the action date for the treatment of locally advanced or metastatic basal cell carcinoma in adults. It is the first drug to be approved for this indication. Erivedge will be available in specialty pharmacies in US within one or two weeks. Roche has the marketing rights for Vismodegib excluding Japan and Korea where Chugai will market. Curis involved in the drug development and will receive royalties from sales.
COMPANIES MENTIONED
ROCHE
ROCHE
